Year None2022202120202019201820172016201520142013 Sep 8 View HTML version View PDF Version Aflibercept 8 mg Meets Primary Endpoints in Two Global Pivotal Trials for DME and wAMD, with a Vast Majority of Patients Maintained on 12- and 16-week Dosing Intervals Sep 5 View HTML version View PDF Version Late-Breaking Dupixent® (dupilumab) Data at ERS 2022 Show Consistent Efficacy and Safety Profile for Up to Two Years in Children Aged 6 to 11 Years with Moderate-to-severe Asthma Sep 4 View HTML version View PDF Version ESMO Presentations of Libtayo® (cemiplimab), Fianlimab and Novel Bispecific Antibodies Showcase Expanding Potential of Regeneron's Oncology Pipeline in Multiple Cancers Aug 25 View HTML version View PDF Version Regeneron Announces Investor Conference Presentations Aug 3 View HTML version View PDF Version Regeneron Reports Second Quarter 2022 Financial and Operating Results Aug 3 View HTML version View PDF Version Novel Costimulatory Bispecific Antibody Shows Encouraging Anti-tumor Activity When Combined with PD-1 Inhibitor Libtayo® (cemiplimab) in Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) Jul 27 View HTML version View PDF Version Regeneron Genetics Center Discovers Rare Mutations In The CIDEB Gene That Protect Against Liver Disease Jul 26 View HTML version View PDF Version Regeneron Announces the 2022 Winners of the Regeneron Prize for Creative Innovation Jul 14 View HTML version View PDF Version Dupixent® (dupilumab) Phase 3 Trial Shows Positive Results in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Jul 6 View HTML version View PDF Version Regeneron to Report Second Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2022 First page « Previous page ‹ Page 1 Current page 2 Page 3 Page 4 Page 5 Page 6 Next page › Last page »